Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of its new IR820 and I...
Thermo Fisher Scientific Inc., the world leader in serving science, proudly announced its role as a founding sponsor of the newly launched LifeSciKY Co...
Gene Solutions, a leader in mitochondrial dysfunction genomics and CNS drug discovery, announces the publication of its platform technology patent. The a...
Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, announced a strategic collaboration with Maxymune Therapeutics, a ...
Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnosti...
Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timeline ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Sapio Sciences, the science-awareTM lab informatics platform, announced a strategic partnership with Ultima Genomics. The collaboration will make m...
Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, ap...
Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the functi...
-IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, inaugurated its expanded LMR Naturals site in Grasse fo...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that first-line treatment with RYBREVANT® (amivantamab-vmj...
© 2025 Biopharma Boardroom. All Rights Reserved.
